Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

FMR LLC trimmed its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 3.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,026,956 shares of the company's stock after selling 1,230,644 shares during the quarter. FMR LLC owned approximately 14.32% of Allogene Therapeutics worth $84,075,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ALLO. Nisa Investment Advisors LLC increased its stake in Allogene Therapeutics by 429.6% in the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company's stock worth $25,000 after purchasing an additional 8,734 shares during the period. Federated Hermes Inc. purchased a new position in Allogene Therapeutics in the 2nd quarter worth about $29,000. Phoenix Wealth Advisors bought a new stake in Allogene Therapeutics during the 2nd quarter valued at about $30,000. Private Advisor Group LLC purchased a new stake in Allogene Therapeutics in the 3rd quarter valued at about $34,000. Finally, Algert Global LLC bought a new position in Allogene Therapeutics in the 2nd quarter worth about $35,000. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Stock Up 2.3 %

Shares of Allogene Therapeutics stock traded up $0.05 on Friday, reaching $2.19. The stock had a trading volume of 2,645,412 shares, compared to its average volume of 2,469,243. The stock has a market capitalization of $459.18 million, a P/E ratio of -1.37 and a beta of 0.83. The company has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.60. Allogene Therapeutics, Inc. has a 1 year low of $1.99 and a 1 year high of $5.78.

Analyst Ratings Changes

Several research firms have recently weighed in on ALLO. William Blair reaffirmed an "outperform" rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Citigroup upped their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Canaccord Genuity Group cut their price target on Allogene Therapeutics from $35.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, August 8th. Piper Sandler lowered their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Finally, Truist Financial reiterated a "buy" rating and set a $14.00 target price (down from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Allogene Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).